Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arrowhead Pharma (NQ: ARWR ) 19.49 +0.26 (+1.35%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,054,848 Open 19.55 Bid (Size) 19.11 (2) Ask (Size) 19.98 (5) Prev. Close 19.23 Today's Range 19.30 - 19.85 52wk Range 17.05 - 39.83 Shares Outstanding 105,736,200 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome November 01, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up October 18, 2024 The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. Via Investor's Business Daily Performance YTD -37.15% -37.15% 1 Month +3.40% +3.40% 3 Month -22.29% -22.29% 6 Month -22.54% -22.54% 1 Year -30.76% -30.76% More News Read More Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) October 14, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity September 23, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran September 10, 2024 From Arrowhead Pharmaceuticals, Inc Via Business Wire Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome September 02, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome August 21, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies August 14, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q3 2024 August 08, 2024 Via InvestorPlace Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results August 08, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street August 08, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) July 29, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results July 24, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday July 05, 2024 Via Benzinga Topics Stocks Exposures US Equities What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients July 05, 2024 Via Investor's Business Daily Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025 June 28, 2024 Via InvestorPlace Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial June 25, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Why Arrowhead Pharmaceuticals (ARWR) Stock Is Seeing Blue Skies June 24, 2024 Via Benzinga Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE June 24, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire 5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More June 24, 2024 Via Benzinga Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday? June 03, 2024 Via Benzinga Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday June 03, 2024 Via Benzinga Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome June 03, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences May 31, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia May 29, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
